ChiCTR2500105091 版本V1.0 版本创建时间2025/06/27 18:16:15 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500105091 

最近更新日期:

Date of Last Refreshed on:

2025-06-27 18:16:11 

注册时间:

Date of Registration:

2025-06-27 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于眼部生物参数和深度学习的儿童青少年屈光度的预测方法

Public title:

A Prediction Method for Refractive Status in Children and Adolescents Based on Ocular Biometric Parameters and Deep Learning

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于眼部生物参数和深度学习的儿童青少年屈光度的预测方法

Scientific title:

A Prediction Method for Refractive Status in Children and Adolescents Based on Ocular Biometric Parameters and Deep Learning

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张卫婕 

研究负责人:

冯雪亮 

Applicant:

WeijieZhang 

Study leader:

XuelaingFeng 

申请注册联系人电话:

Applicant telephone:

+86 195 1143 0082

研究负责人电话:

Study leader's telephone:

+86 139 3451 7456

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

541828126@qq.com

研究负责人电子邮件:

Study leader's E-mail:

13934517456@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山西省太原市爱尔眼科医院

研究负责人通讯地址:

山西省太原市杏花岭区府东街100号

Applicant address:

No.1 South Inner Ring, Yingze District, Taiyuan City, Shanxi Province

Study leader's address:

No. 100, Fudong Street, Xinghualing District, Taiyuan City, Shanxi Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

太原爱尔眼科医院

Applicant's institution:

Taiyuan Eye Hospital

研究负责人所在单位:

山西省眼科医院

Affiliation of the Leader:

Shanxi Province Eye Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SXYYLL-KSSC010

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山西省眼科医院以下伦理审查

Name of the ethic committee:

Medical Ethics Review, Shanxi Provincial Ophthalmic Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-01-28 00:00:00

伦理委员会联系人:

高妍

Contact Name of the ethic committee:

YanGao

伦理委员会联系地址:

山西省太原市杏花岭区府东街100号

Contact Address of the ethic committee:

No. 100, Fudong Street, Xinghualing District, Taiyuan City, Shanxi Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 176 3559 1066

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山西省眼科医院

Primary sponsor:

Shanxi Province Eye Hospital

研究实施负责(组长)单位地址:

山西省太原市杏花岭区府东街100号

Primary sponsor's address:

No. 100, Fudong Street, Xinghualing District, Taiyuan City, Shanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山西省

市(区县):

太原市

Country:

China

Province:

Shanxi

City:

单位(医院):

山西省眼科医院

具体地址:

山西省太原市杏花岭区府东街100号

Institution
hospital:

Shanxi Province Eye Hospital

Address:

No. 100, Fudong Street, Xinghualing District, Taiyuan City, Shanxi Province

经费或物资来源:

山西省科技厅

Source(s) of funding:

Science and Technology Innovation Base Construction Project of Shanxi Provincial Department of Science and Technology (Grant No. YDZJSX2022B015)

Target disease:

Myopia

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

基于眼生物参数及深度学习构建预测模型,以研究儿童青少年屈光度的进展。  

Objectives of Study:

To develop a predictive model based on ocular biometric parameters and deep learning for studying the progression of refractive errors in children and adolescents.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.5-18岁的儿童青少年;2.能够配合完成验光检查;3.能够配合完成生物测量检查;4.可以接收长期随访。

Inclusion criteria

1. Children and adolescents aged 5 to 18 years; 2.Ability to cooperate with refractive error testing; 3.Ability to cooperate with biometry measurements; 4 Willingness to participate in long-term follow-up.

排除标准:

排除标准:1.配戴近视防控眼镜和/或接受近视防控干预措施;2.有眼前后节器质性病变;3.有影响配合检查的全身病。

Exclusion criteria:

Exclusion Criteria: 1. Use of myopia control glasses and/or participation in myopia control interventions; 2.Presence of organic diseases in the anterior or posterior segments of the eye; 3. Systemic diseases that may interfere with cooperation during examinations; 4.History of refractive surgery or specific refractive abnormalities (e.g., high myopia, astigmatism).

研究实施时间:

Study execute time:

From 2022-07-01 00:00:00 To 2025-06-04 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-01-28 00:00:00 To 2024-02-28 00:00:00  

干预措施:

Interventions:

组别:

观察组

样本量:

559

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山西省 

市(区县):

 

Country:

China 

Province:

shanxi 

City:

 

单位(医院):

山西省眼科医院 

单位级别:

三甲 

Institution
hospital:

Shanxi Province Eye Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

眼轴

指标类型:

主要指标

Outcome:

axial lengths

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

屈光度

指标类型:

主要指标

Outcome:

Refractive Status

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜曲率

指标类型:

主要指标

Outcome:

corneal curvature

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

晶体厚度

指标类型:

次要指标

Outcome:

len thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

前房深度

指标类型:

次要指标

Outcome:

chamber depth

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 6 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在文章发表后,将数据上传至“国家生物信息中心。https://ngdc.cncb.ac.cn/gsub/submit/bioproject/PRJCA041427

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After publication, the dataset will be submitted to the China National center for Bioinformation.(https://ngdc.cncb.ac.cn/gsub/)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

在山西省眼科医院行眼部生物测量和验光检查后数据会记录于电脑系统,回顾性收集了电子记录,并进行整理。在文章发表后,将数据上传至“国家生物信息中心”。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

In Shanxi Eye Hospital, after performing ocular biometry and optometric examinations, the data are recorded into the computer system. Retrospective collection of electronic records was conducted, followed by data organization. After publication, the dataset will be submitted to the China National center for Bioinformation.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-27 18:16:11